Testosterone reduces AGTR1 expression to prevent β-cell and islet apoptosis from glucotoxicity

Suwattanee Kooptiwut1, Wanthanee Hanchang2, Namoiy Semprasert2

  • 1Department of PhysiologyDepartment of AnatomyDivision of Molecular MedicineDepartment of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand suwattanee.koo@mahidol.ac.th.

Insights

Testosterone protects pancreatic beta cells from high glucose damage by reducing the expression of the angiotensin II type 1 receptor (AGTR1) and its signaling pathway, thus preventing apoptosis. This finding offers new insights into managing type 2 diabetes in hypogonadal men.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Metabolic Diseases

Background:

  • Hypogonadism in men correlates with increased type 2 diabetes incidence.
  • Testosterone protects pancreatic beta cells from apoptosis induced by toxins like high glucose.
  • High glucose induces pancreatic beta cell apoptosis via the local renin-angiotensin-aldosterone system (RAAS).

Purpose of the Study:

  • To investigate testosterone's protective mechanism against high glucose-induced pancreatic beta cell apoptosis.
  • To determine if testosterone modulates the pancreatic RAAS pathway.

Main Methods:

  • Cultured rat insulinoma (INS-1) cells and isolated mouse islets in high-glucose media with or without testosterone, losartan, or Angiotensin II (Ang II).
  • Assessed apoptosis, cleaved caspase 3, oxidative stress, and expression of AGTR1 and p47(phox) mRNA/protein.
  • Utilized AGTR1 knockdown experiments to confirm pathway involvement.

Main Results:

  • Testosterone and losartan similarly reduced beta cell apoptosis.
  • Testosterone significantly decreased AGTR1 protein expression under high-glucose conditions, with or without Ang II.
  • Testosterone attenuated superoxide production and decreased AGTR1 and p47(phox) expression in high-glucose media.
  • Testosterone had no effect on beta cells in basal glucose conditions.
  • High glucose did not increase apoptosis in AGTR1 knockdown cells.

Conclusions:

  • Testosterone prevents high glucose-induced pancreatic beta cell apoptosis.
  • This protection is mediated by reducing the expression of the angiotensin II type 1 receptor (AGTR1) and its signaling pathway.
  • Testosterone's role in regulating the pancreatic RAAS offers a potential therapeutic target for diabetes management.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
9.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
6
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K